Melanotan I
Alpha-MSH analog · Also known as Afamelanotide, Scenesse, CUV1647, NDP-alpha-MSH
What is Melanotan I?
A linear analog of alpha-melanocyte stimulating hormone (alpha-MSH) that stimulates melanin production. FDA-approved (as Scenesse) for erythropoietic protoporphyria (EPP), a rare photosensitivity disorder.
Melanotan I (afamelanotide) is a 13-amino-acid linear peptide analog of alpha-MSH with a norleucine substitution that increases receptor binding and metabolic stability. Unlike Melanotan II, it is highly selective for the MC1R receptor and does not cause sexual side effects or appetite suppression.
Benefits & evidence
How it works
Melanotan I binds selectively to the melanocortin 1 receptor (MC1R) on melanocytes in the skin. This activates the cAMP signaling pathway, upregulating tyrosinase and other enzymes in the melanin synthesis pathway.
The result is increased production of eumelanin (the brown/black protective pigment), which absorbs UV radiation and protects skin cells from DNA damage. Unlike Melanotan II, it has minimal affinity for MC3R and MC4R, so it does not affect appetite or sexual function.
As Scenesse, it is administered as a subcutaneous implant that slowly releases over 60 days.
Dosing information
Typical dosing protocol
16 mg implant
Every 60 days16 mg implant
Every 60 daysFDA-approved as a subcutaneous implant for EPP. Research peptide versions exist as injectable solutions, but dosing protocols are not standardized.
Side effects
Most side effects tend to improve as your body adjusts.